Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis

被引：0

作者：

Bresse, Xavier ^{[1
]}

Annemans, Lieven ^{[2
]}

Preaud, Emmanuelle ^{[1
]}

Bloch, Karine ^{[1
]}

Duru, Gerard ^{[3
]}

Gauthier, Aline ^{[4
]}

机构：

[1] Sanofi Pasteur MSD, F-69367 Lyon 07, France

[2] Univ Ghent, B-9000 Ghent, Belgium

[3] CYKLAD Grp, F-69130 Rillieux La Pape, France

[4] Amaris, London NW1 8NZ, England

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2013年 / 13卷 / 03期

关键词：

cost-effectiveness; herpes zoster; herpes zoster vaccine; postherpetic neuralgia; vaccination; QUALITY-OF-LIFE; ECONOMIC-EVALUATION; HEALTH-CARE; PAIN; PREVENTION; SHINGLES; BURDEN; VARICELLA; IMPACT; EPIDEMIOLOGY;

D O I：

10.1586/ERP.13.19

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between (sic)9513 and 12,304 per quality-adjusted life year gained, corresponding to (sic)2240-2651 per HZ case avoided and (sic)3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.

引用

页码：393 / 406

页数：14

共 50 条

[41] Therapy of herpes zoster and postherpetic neuralgia
Huening, S.
von Duecker, L.
Kohl, W. K.
Nashan, D.
[J]. HAUTARZT, 2019, 70 (08): : 645 - 656
[42] Management of herpes zoster and postherpetic neuralgia
Tyring, Stephen K.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (06) : S136 - S142
[43] Treatment of herpes zoster and postherpetic neuralgia
Johnson, RW
Dworkin, RH
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7392): : 748 - 750
[44] Commentary on Herpes Zoster and Postherpetic Neuralgia
Cohen, Elisabeth J.
[J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E3218 - E3219
[45] Acute herpes zoster and postherpetic neuralgia
Pernak, J
[J]. MANAGEMENT OF PAIN A WORLD PERSPECTIVE III, 1998, : 69 - 73
[46] Treatment of Herpes Zoster and Postherpetic Neuralgia
Schulzeck, Sabine
Gleim, Martin
[J]. ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2009, 44 (10): : 644 - 650
[47] Herpes zoster and postherpetic neuralgia in the elderly
Lee, VK
Simpkins, L
[J]. GERIATRIC NURSING, 2000, 21 (03) : 132 - 136
[48] Acute herpes zoster and postherpetic neuralgia
Elena Catala
Marta Ferrandiz
[J]. Current Review of Pain, 1999, 3 (2): : 130 - 136
[49] Herpes Zoster (Shingles) and Postherpetic Neuralgia
Sampathkumar, Priya
Drage, Lisa A.
Martin, David P.
[J]. MAYO CLINIC PROCEEDINGS, 2009, 84 (03) : 274 - 280
[50] Managing Herpes Zoster and Postherpetic Neuralgia
Galluzzi, Katherine E.
[J]. JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2009, 109 (06): : S7 - S12

← 1 2 3 4 5 →